ARWR: Encouraging early data for obesity programs

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Encouraging Early Data for Obesity Programs On January 6, 2026, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced preliminary results for the company’s investigational treatments for obesity, ARO-INHBE and ARO-ALK7. The company also held a webinar to discuss the results. The slides and the webinar can be accessed here. The data showed that ARO-INHBE, both as...